GeneDx Holdings Corp - Class A

Research GeneDx Holdings Corp - Class A (WGS) on Bullrun: market cap USD 2.60B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 2.60B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 427.54M-USD 21.00MUSD 14.26M69.7%-0.73USD 105.00MUSD 52.72MUSD 308.18M
FY2024USD 305.45M-USD 52.30M-USD 33.99M63.6%-1.94USD 85.21MUSD 53.12MUSD 245.25M
FY2023USD 202.57M-USD 175.80M-USD 185.40M44.4%-7.23USD 99.68MUSD 53.19MUSD 228.02M
FY2022USD 234.69M-USD 548.98M-USD 326.31M-11.4%-53.63USD 123.93MUSD 11.00MUSD 253.71M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 2.60Bn/an/an/a
20252025-12-31USD 3.80Bn/an/an/a
20242024-12-31USD 2.15Bn/an/an/a
20232023-12-29USD 71.18Mn/an/an/a
20222022-12-30USD 102.09Mn/an/an/a
20212021-12-31USD 1.08Bn/an/an/a

About GeneDx Holdings Corp - Class A

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is GeneDx Holdings Corp - Class A's market cap?

GeneDx Holdings Corp - Class A's market capitalization is USD 2.60B.

What does GeneDx Holdings Corp - Class A do?

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.